L-Cysteine, S-((2R)-2-((1-iminoethyl)amino)propyl)- | 511272-61-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Cysteine, S-((2R)-2-((1-iminoethyl)amino)propyl)-
• 英文别名: (2R)-2-amino-3-[(2R)-2-(1-aminoethylideneamino)propyl]sulfanylpropanoic acid
• CAS: 511272-61-0
• 化学式: C₈H₁₇N₃O₂S
• 分子量: 219.31
• InChiKey: KAXFOSOXUNYWRV-VDTYLAMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] NITRIC OXIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE SYNTHASE D'OXYDE NITRIQUE
  申请人：GLAXO GROUP LIMITED

  公开号：WO1999062875A1

  公开（公告）日：1999-12-09

  (EN) The present invention relates to novel amidino compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof; wherein R1 is selected from C1-4 alkyl, C3-4 cycloalkyl, C1-4 hydroxyalkyl, and C1-4 haloalkyl; to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.(FR) L'invention concerne de nouveaux composés d'amidino représentés par la formule (I) ou un de leurs sels, solvates ou dérivés fonctionnels sur le plan physiologique ; dans laquelle R1 est sélectionné dans alkyle C1-C4, cycloalkyle C3-C4, hydroxyalkyle C1-C4 et haloalkyle C1-C4; un procédé servant à les préparer, des compositions pharmaceutiques les contenant et leur mise en application thérapeutique, en particulier, en tant qu'inhibiteurs sélectifs de synthase inductible d'oxyde nitrique.

  本发明涉及一种新型的amidino化合物，其化学式为(I)，或其盐、溶剂化合物或生理功能衍生物；其中R1选自C1-4烷基、C3-4环烷基、C1-4羟基烷基和C1-4卤代烷基；以及制备它们的方法、含有它们的制药组合物，以及它们在治疗中的应用，特别是它们作为诱导型一氧化氮合酶的选择性抑制剂。
• Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor
  申请人：——

  公开号：US20040077639A1

  公开（公告）日：2004-04-22

  Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.

  本文描述了用于预防和治疗呼吸系统疾病或状况的治疗方法，该方法包括向需要治疗的受试者施用一种选择性抑制诱导型一氧化氮合酶的有效剂量。
• Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
  申请人：——

  公开号：US20040087653A1

  公开（公告）日：2004-05-06

  Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.

  本文描述了用于预防和治疗呼吸系统疾病或症状的治疗方法，其中的方法包括向需要治疗的对象施用诱导型一氧化氮合酶选择性抑制剂的有效剂量。
• Methods for treatment and prevention of gastrointestinal conditions
  申请人：——

  公开号：US20040127569A1

  公开（公告）日：2004-07-01

  Therapeutic methods for the prevention and treatment of conditions and diseases of the gastrointestinal tract involving an overproduction of nitric oxide by inducible nitric oxide synthase are described, the methods including administering to a subject in need thereof a therapeutically effective amount of a selective inhibitor of inducible nitric oxide synthase (iNOS). The methods also include the use of selective inhibitors of iNOS in combination with other therapeutic agents, including antimicrobial agents and antisecretory agents.

  本文描述了用于预防和治疗涉及诱导型一氧化氮合酶过度产生的胃肠道疾病和病症的治疗方法，其中包括向需要治疗的受试者施用选择性诱导型一氧化氮合酶（iNOS）抑制剂的治疗有效量。该方法还包括将选择性iNOS抑制剂与其他治疗药物（包括抗微生物药物和抗分泌药物）结合使用。
• Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
  申请人：Hsu Y. Chung

  公开号：US20050203082A1

  公开（公告）日：2005-09-15

  A combination therapy comprising administration of a carbamoylating chemotherapeutic agent in conjunction with administration of a selective iNOS inhibitor compound is disclosed. Optionally, resection and radiation therapy are provided with the therapeutic combination. A medicament comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound together with a pharmaceutically acceptable carrier is further disclosed. A kit comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound is further disclosed.

  本发明揭示了一种联合治疗方案，包括给予一种氨基甲酰化化学治疗药物，同时给予一种选择性iNOS抑制剂化合物。可选地，该治疗组合还提供切除和放射治疗。此外，本发明还揭示了一种药物，包括一种氨基甲酰化化学治疗药物和一种选择性iNOS抑制剂化合物，以及一种药学上可接受的载体。本发明还揭示了一种套装，包括一种氨基甲酰化化学治疗药物和一种选择性iNOS抑制剂化合物。